Context Therapeutics Stock Analysis
| CNTX Stock | USD 0.77 0.05 6.10% |
Context Therapeutics is overvalued with Real Value of 0.72 and Hype Value of 0.77. The main objective of Context Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Context Therapeutics is worth, separate from its market price. There are two main types of Context Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Context Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Context Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Context Stock trading window is adjusted to America/New York timezone.
Context |
Context Stock Analysis Notes
About 97.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Context Therapeutics recorded a loss per share of 0.88. The entity had not issued any dividends in recent years. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Context Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Context Therapeutics please contact the company at 267 225 7416 or go to https://www.contexttherapeutics.com.Context Therapeutics Investment Alerts
| Context Therapeutics generated a negative expected return over the last 90 days | |
| Context Therapeutics has high historical volatility and very poor performance | |
| Context Therapeutics has some characteristics of a very speculative penny stock | |
| Context Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (23.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Context Therapeutics currently holds about 42.92 M in cash with (21.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 97.0% of the company shares are held by institutions such as insurance companies |
Context Therapeutics Upcoming and Recent Events
Earnings reports are used by Context Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Context Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 57.76 M.Technical Drivers
As of the 21st of March, Context Therapeutics shows the Mean Deviation of 4.74, standard deviation of 6.37, and Risk Adjusted Performance of (0.02). Context Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Context Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Context Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Context Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Context Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Context Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Context Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Context Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Context Therapeutics Outstanding Bonds
Context Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Context Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Context bonds can be classified according to their maturity, which is the date when Context Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Context Therapeutics Predictive Daily Indicators
Context Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Context Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Context Therapeutics Forecast Models
Context Therapeutics' time-series forecasting models are one of many Context Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Context Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Context Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Context Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Context shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Context Therapeutics. By using and applying Context Stock analysis, traders can create a robust methodology for identifying Context entry and exit points for their positions.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Context Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Context Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.